Precision IO presents Epione robotic MSK ablation data at SRS meeting
The presentation lands as Precision IO's 60-patient feasibility study of Epione is still enrolling, so the SRS session showcases physician experience rather than trial results.
Executive Summary
- Precision IO Group is set to present physician experience with its robotic ablation platform at a surgical society meeting, ahead of any results from the device's own feasibility study.
- This is a conference session built around clinician testimonials, not a data disclosure from the ongoing trial the device is enrolling under.
- The underlying feasibility study is enrolling on schedule, with a stable timeline and no signs of operational strain, but its result has not yet posted.
- The device sits in a landscape with no closely comparable trial sharing its specific mechanism, though the broader field of percutaneous MSK and introducer-assistance devices includes several active programs.
The presentation
Precision IO Group, the parent company of NeuWave Medical and Quantum Surgical, will present at the Society of Robotic Surgery Annual Meeting in Hollywood, Florida, running July 22 through 26, 2026. Sean Tutton, a professor of radiology and orthopedics, will speak in a session titled "Orthopedics: Image-Guided Robotic Ablation for MSK Tumor Ablation" on July 23. Govindarajan Narayanan, who performed the first U.S. Epione procedure, will present separately on the platform's telesurgical capabilities on July 26. Precision IO CEO Kurt Azarbarzin will also join an investor-session panel on innovative robotic technologies. PrecisionPrecision IO Group to Present Epione® Robotic Platform and Remote Intervention Program at Society of Robotic Surgery Annual MeetingJul 20, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The trial behind it
The session is tied to NCT07325578, a U.S. prospective, non-randomized, open-label study evaluating the Epione device against freehand needle placement in CT- or CBCT-guided percutaneous procedures of the pelvis and spine. The study targets 60 adult patients under general anesthesia, with feasibility as its primary endpoint and accuracy and adverse events as secondary measures. It dosed its first patient on April 28, 2026, moved to Recruiting status on May 5, and carries a primary completion date of September 1, 2026, after a one-month shift from an original August 1 date. Enrollment has not changed from its original 60-patient target, a pattern the trial's own operational baseline flags as routine. NCT07325578U.S. Prospective Evaluation of EPIONE Device for Percutaneous MSK ProceduresNCT07325578
What the presentation covers
Narayanan said in the disclosure that robotic assistance "is now a routine part of how I plan and perform percutaneous ablations," and that the next barrier is geographic access rather than the technology itself. Precision IO also used the meeting to outline a remote intervention program, still in development, aimed at extending trajectory planning and results assessment to physicians outside major treatment centers. Azarbarzin said the goal is to "continue to extend access to cancer care for patients everywhere". Neither disclosure includes new feasibility, accuracy, or safety data from NCT07325578 itself; the presentation draws on physician experience with Epione rather than the trial's own endpoint results. PrecisionPrecision IO Group to Present Epione® Robotic Platform and Remote Intervention Program at Society of Robotic Surgery Annual MeetingJul 20, 2026
The competitive frame
Epione's mechanism, described in the registry as assistance for introducer placement, has no directly comparable trial sharing that specific mechanism among the programs surfaced in the same-mechanism field, which instead consists mostly of transcatheter valve and vascular-closure devices with different indications. Within the broader percutaneous musculoskeletal procedures field, the closest adjacent programs include a spinal disc-augmentation device and several oncology drug trials with unrelated mechanisms, none of which compete directly with a robotic introducer-guidance platform. Precision IO Group has completed three of its four registered trials with no terminations, a track record consistent with the low operational-risk read on this study.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.